HSA & FSA accepted; best-value for top quality care

Same-day mental health, weight loss, and primary care appointments available

Excellent

based on 0 reviews

Accept major insurances and cash-pay

HSA & FSA accepted; best-value for top quality care

Same-day mental health, weight loss, and primary care appointments available

Excellent

based on 0 reviews

Accept major insurances and cash-pay

Back

Published: Apr 28, 2026

Psychiatric NP Scope of Practice for Weight Loss/GLP-1

Written by Klarity Editorial Team

Published: Apr 28, 2026

Psychiatric NP Scope of Practice for Weight Loss/GLP-1

Table of contents

If you’re a psychiatrist or PMHNP wondering whether you can legally prescribe weight loss medications like semaglutide (Ozempic/Wegovy) or phentermine — especially via telehealth — you’re not alone. The explosion of GLP-1 weight loss treatments has blurred the lines between specialties, and many psychiatric providers are fielding patient requests or considering adding weight management to their practice.

The short answer: Yes, psychiatrists (MD/DO) can legally prescribe weight loss medications. You hold an unrestricted medical license, which gives you broad prescribing authority beyond mental health. But there’s a significant gap between can and should — and an even bigger gap between prescribing occasionally and running a weight loss practice.

This guide breaks down the regulatory reality: federal DEA rules for controlled substances via telehealth, state-specific prescribing requirements, scope of practice considerations for psychiatric providers, and the practical compliance steps you need if you’re going to treat obesity remotely. Whether you’re helping a patient manage antipsychotic-induced weight gain or exploring weight management as a revenue stream, here’s what you need to know to stay compliant and avoid regulatory pitfalls.

The Current Federal Landscape: DEA Telehealth Rules Through 2026

What Changed (and What Hasn’t)

Pre-pandemic, the Ryan Haight Online Pharmacy Act required an in-person medical evaluation before any provider could prescribe controlled substances via telemedicine to a new patient. During COVID-19’s Public Health Emergency, that requirement was temporarily waived nationwide, enabling telehealth providers to prescribe controlled medications — including Schedule IV appetite suppressants like phentermine — without ever meeting patients face-to-face.

Where we are now: In January 2026, HHS and the DEA announced a fourth extension of these telehealth flexibilities through December 31, 2026 (www.hhs.gov). This means you can continue prescribing controlled substances via telehealth to new patients nationwide without an initial in-person exam — but only until the end of 2026 or until new permanent rules are finalized.

The DEA is actively developing those permanent regulations. Proposed rules include a ‘Special Telemedicine Registration’ pathway for Schedule III–V controlled substances and possible state-based restrictions for Schedule II stimulants (www.dea.gov). The message is clear: plan for a compliance shift in 2027.

What This Means for Weight Loss Medications

Here’s the critical distinction: Most newer weight loss medications aren’t controlled substances.

GLP-1 agonists (semaglutide/Wegovy, tirzepatide/Zepbound, liraglutide/Saxenda) are not DEA-scheduled drugs. You can prescribe them via telehealth under standard medical practice — no DEA restrictions apply (www.medicaldirectorco.com).
Phentermine (Adipex-P, Lomaira) is a Schedule IV controlled substance. Under the current DEA extension, you can prescribe it via telehealth to new patients. But you need a DEA registration, must check your state’s Prescription Drug Monitoring Program (PDMP), and should prepare for potential rule changes in 2027.
Other controlled weight loss drugs (older amphetamines, Schedule II stimulants) face stricter scrutiny. Some states already prohibit teleprescribing Schedule II drugs for weight loss (more on state rules below).

Reality check: Even when federal law allows teleprescribing controlled substances, state laws often impose stricter requirements. You must comply with both — and the stricter rule always wins.

State Laws Trump Federal Flexibilities: Know Your Jurisdiction

The DEA extension doesn’t override state medical boards. Several states have maintained or reinstated in-person exam requirements for controlled substances, while others have specific obesity treatment regulations regardless of modality.

New York: The Strictest State for Controlled Substances

New York explicitly requires an in-person medical evaluation before prescribing any controlled substance to a patient, with only narrow exceptions (10 NYCRR §80.63, amended May 2025) (www.cchpca.org).

Exceptions include:

A different NY-licensed provider examined the patient in person within the past 12 months and shared records
You’re covering for a colleague who saw the patient in person
Emergency situation with an existing patient (5-day supply maximum) (www.law.cornell.edu)

What this means: If you’re treating a New York patient via telehealth and want to prescribe phentermine, you cannot do so purely online for a new patient. You need to either see them in person first, coordinate with another provider who has, or find a non-controlled alternative (like a GLP-1).

For non-controlled weight loss medications, New York allows standard telehealth prescribing with no in-person requirement.

Florida: Psychiatric vs. Weight Loss Carve-Outs

Florida prohibits teleprescribing Schedule II controlled substances except for psychiatric disorders, inpatient/hospice care, or nursing home patients (Fla. Stat. §456.47) (florida.public.law).

Translation: A psychiatrist in Florida can prescribe Adderall (Schedule II) via telehealth for ADHD because it’s treating a psychiatric disorder. But you cannot prescribe Schedule II stimulants via telehealth solely for weight loss — obesity isn’t a psychiatric condition under Florida law.

Good news: Phentermine (Schedule IV) isn’t restricted by Florida’s telehealth statute. You can prescribe it remotely for weight loss as long as you follow Florida’s obesity treatment standards (more below).

Florida’s Obesity Prescribing Requirements (FAC 64B8-9.012):

Patient must have BMI ≥30 (or ≥27 with comorbidities) (regulations.justia.com)
Document a thorough evaluation (history, physical exam, appropriate tests)
Obtain written informed consent outlining medication risks (regulations.justia.com)
Re-evaluate the patient at least every 3 months while on medication (regulations.justia.com)
Provide each patient with Florida’s ‘Weight-Loss Consumer Bill of Rights’

These rules apply to all physicians prescribing obesity medications in Florida, regardless of specialty (www.goodwinlaw.com).

Texas: Permissive but Protocols Matter

Texas has no blanket prohibition on telehealth prescribing of controlled substances for weight loss. The state requires a valid practitioner-patient relationship established via live video (or store-and-forward with audio consultation), but doesn’t mandate an initial in-person visit (www.cchpca.org).

Key Texas requirements:

Use synchronous audiovisual interaction for controlled substance prescriptions
Check the Texas Prescription Monitoring Program (PMP) before prescribing controlled medications (www.medicaldirectorco.com)
Within 72 hours of a telehealth encounter, provide follow-up instructions and (with patient consent) send a report to their primary care provider (www.cchpca.org)
Maintain documentation equivalent to in-person visits

Texas’s corporate practice of medicine doctrine means non-physicians can’t independently operate medical practices — ensure proper ownership structure if setting up a telehealth service.

California: Telehealth-Friendly with PDMP Requirements

California considers a telehealth exam equivalent to an in-person exam for prescribing purposes, as long as the standard of care is met. No special in-person requirement exists for controlled substances via telehealth (www.medicaldirectorco.com).

California-specific requirements:

Obtain and document patient consent for telehealth (B&P Code §2290.5) (www.medicaldirectorco.com)
Query the CURES PDMP before the first prescription of any Schedule II–IV drug and at least every 4 months for ongoing therapy (www.medicaldirectorco.com)
Use electronic prescribing for all medications (including controlled substances)
Comply with California’s strict Corporate Practice of Medicine doctrine — only physician-owned entities can provide medical services (www.medicaldirectorco.com)

Notable: California Medi-Cal will stop covering GLP-1 medications for weight loss effective January 2026, classifying them as non-covered services (www.cmadocs.org). This likely pushes more patients toward cash-pay telehealth models.

Pennsylvania & Illinois: Federal Rules Apply with PDMP Mandates

Both states defer largely to federal law for telehealth prescribing of controlled substances, meaning the current DEA extension allows it. However:

Pennsylvania:

Must check PA PDMP before first opioid/benzodiazepine prescription and each time thereafter (www.pa.gov)
For other controlled substances (stimulants, phentermine), check PDMP before first prescription and as clinically indicated
NPs require collaborative agreements with physicians to prescribe (no independent practice)

Illinois:

Must check Illinois PMP before prescribing Schedule II narcotics; best practice is checking for all controlled substances
Advanced Practice Nurses can achieve Full Practice Authority after 4,000 clinical hours, allowing independent prescribing including controlled substances
Telehealth explicitly allowed for establishing patient relationships; audio-only permitted in some cases (www.cchpca.org)

Scope of Practice: Psychiatrists vs. PMHNPs for Weight Loss

For Psychiatrists (MD/DO)

You have full legal authority to prescribe weight loss medications. Your unrestricted medical license allows you to treat conditions outside your specialty, provided you practice competently and meet the standard of care.

Practical considerations:

Clinical competence matters more than legal permission. Medical boards expect you to practice within your knowledge and training. Prescribing a GLP-1 occasionally for antipsychotic-induced weight gain is different from running a weight loss practice.
Follow obesity treatment guidelines. Document BMI, rule out endocrine causes if appropriate, discuss diet/exercise, obtain informed consent about risks. Some states (like Florida and New Jersey) explicitly require these steps (www.goodwinlaw.com).
Be mindful of psychiatric implications. Phentermine is a stimulant — could it worsen anxiety or trigger mania in bipolar patients? GLP-1s can cause nausea that might affect medication adherence. Consider drug interactions with psychotropics.
Coordinate care. Many state medical boards expect you to communicate with the patient’s primary care provider, especially for long-term weight management. Document referrals when appropriate.
Consider additional certification. While not legally required, board certification in Obesity Medicine (through the American Board of Obesity Medicine) strengthens your credibility and demonstrates commitment to practicing within scope.

For Psychiatric Nurse Practitioners (PMHNPs)

The regulatory picture is murkier for psychiatric NPs. Your scope of practice is defined by your training and certification in mental health, not general medical conditions.

Key limitations:

State boards scrutinize scope: Prescribing solely for obesity (a metabolic condition) may be viewed as outside a psychiatric NP’s training. In states like Florida and Texas, NPs must practice within their certified population focus (florida.public.law).
Physician oversight often required: Even in states with ‘independent practice’ for NPs, most boards require NPs to have collaborative agreements or protocols when venturing outside their specialty. A PMHNP treating obesity would typically need a family practice or internal medicine physician collaborator — not another psychiatrist.
California example: NPs under AB 890 (effective through 2026) can achieve independent practice in their certified field after meeting experience requirements (www.medicaldirectorco.com). But a psych NP’s ‘field’ is mental health — treating obesity independently could still raise scope questions.

Safer approaches for PMHNPs:

Treat obesity as a comorbidity of mental health conditions. If you’re managing a patient’s depression and addressing binge eating disorder or medication-induced weight gain, you’re staying within psychiatric scope.
Establish physician collaboration. Partner with a primary care physician or endocrinologist who can oversee the weight management protocol and provide consultation.
Consider dual certification. Some NPs pursue additional certification as Family Nurse Practitioners to broaden their scope — though this requires significant additional training.
Focus on non-controlled medications. GLP-1s aren’t controlled substances and are generally lower-risk from a regulatory perspective than prescribing phentermine outside your scope.

The Clinical and Ethical Scrutiny on Weight Loss Telehealth

Weight management via telehealth is under intense professional and regulatory scrutiny. A February 2025 survey found that over half of primary care physicians express concerns about telehealth GLP-1 prescribers, citing ‘clinically inappropriate prescribing’ and poor continuity of care (www.fiercehealthcare.com).

Why the scrutiny?

Inadequate evaluations: Some online services prescribe based on questionnaires alone, without proper medical history or physical assessment
Lack of follow-up: GLP-1 medications require dose titration and monitoring for side effects; some telehealth companies don’t ensure adequate follow-up
Compounded medications: Use of compounded semaglutide (not FDA-approved formulations) has raised safety flags (www.fiercehealthcare.com)
Coordination gaps: Primary care doctors report finding out about their patients’ telehealth weight loss prescriptions after the fact, creating care fragmentation

What this means for you: Don’t be part of the problem. If you’re going to prescribe weight loss medications via telehealth:

Conduct comprehensive evaluations. Live video visits, not just forms. Document vital signs if obtainable (home blood pressure readings), review relevant labs, assess for contraindications.
Establish robust follow-up protocols. Monthly check-ins initially, then at minimum quarterly (Florida requires every 3 months (www.goodwinlaw.com), Virginia every 30 days (www.goodwinlaw.com)).
Prescribe FDA-approved formulations. Avoid compounded versions unless there’s a genuine shortage and you can verify pharmacy quality.
Coordinate with primary care. With patient consent, inform their PCP that you’re prescribing weight loss medication. Better yet, have the patient see their PCP for baseline labs and blood pressure monitoring.
Incorporate lifestyle counseling. Medications aren’t magic. States like New Jersey require documentation of diet and exercise counseling (www.goodwinlaw.com). Even if not mandated, it’s standard of care.

Practical Compliance Checklist for Psychiatric Providers

Before You Start Prescribing Weight Loss Medications via Telehealth:

Licensure & Registration:

[ ] Confirm you’re licensed in every state where patients are located (not where you’re located)
[ ] Obtain DEA registration if prescribing controlled substances (phentermine)
[ ] Register with state PDMP systems where required

Policies & Protocols:

[ ] Develop written protocols for obesity evaluation (BMI criteria, medical history requirements, contraindications)
[ ] Create informed consent documents covering medication risks, lifestyle changes, and treatment alternatives
[ ] Establish follow-up schedules (at minimum: monthly for first 3 months, then quarterly)
[ ] Set up care coordination process with patients’ primary care providers

Technology & Documentation:

[ ] Use HIPAA-compliant telehealth platform with video capability
[ ] Implement electronic prescribing system (required in most states for controlled substances)
[ ] Integrate PDMP checking into your workflow
[ ] Create documentation templates covering required elements (BMI, comorbidities, informed consent, lifestyle counseling)

State-Specific Requirements:

[ ] Verify your state’s telehealth prescribing rules for controlled substances
[ ] Check if your state has specific obesity treatment regulations (Florida, New Jersey, Virginia have detailed requirements)
[ ] Confirm PDMP query requirements and timing (some states require checking before every controlled substance prescription)
[ ] Understand your state’s corporate practice of medicine rules if establishing a practice entity

Clinical Competence:

[ ] Consider obesity medicine CME or certification if treating obesity as a primary focus
[ ] Review current obesity treatment guidelines (AMA, Obesity Medicine Association)
[ ] Establish relationships with specialists for complex cases (endocrinology, bariatric surgery)
[ ] Develop protocols for managing common GLP-1 side effects and when to discontinue therapy

For Every Patient Encounter:

Initial Evaluation:

[ ] Conduct live video visit (audio-only generally insufficient for new prescriptions)
[ ] Document comprehensive medical history including psychiatric conditions, medications, weight loss attempts
[ ] Calculate and record BMI; document comorbidities if BMI 27-29.9
[ ] Screen for contraindications (pregnancy, personal/family history of thyroid cancer for GLP-1s, uncontrolled hypertension for phentermine)
[ ] Review recent labs if available (TSH, glucose, lipids); order if not recent
[ ] Check PDMP before prescribing controlled substances
[ ] Obtain documented informed consent covering risks, benefits, alternatives
[ ] Discuss lifestyle modifications (diet, exercise, behavioral changes)
[ ] Provide written treatment plan including follow-up schedule

Ongoing Management:

[ ] Schedule follow-ups per state requirements (monthly initially, then at least quarterly)
[ ] Document weight changes, side effects, medication adherence at each visit
[ ] Reassess appropriateness of continuing therapy (Is there 5% weight loss after 12-16 weeks? If not, consider discontinuing)
[ ] Check PDMP periodically if prescribing controlled substances
[ ] Communicate with primary care provider (document attempts and patient consent)
[ ] Adjust doses per FDA guidance (especially important for GLP-1 dose titration)

The Economics: Is This Worth Your Time?

Let’s be honest about the business case, because adding weight management to a psychiatric practice isn’t trivial.

Revenue potential:

GLP-1 prescriptions for weight loss are mostly cash-pay (few insurers cover for obesity without diabetes). Initial consults might run $150-300, monthly follow-ups $75-150.
If you see 20 weight loss patients monthly with $100 average visit reimbursement, that’s $24,000 annual revenue.
But factor in your time: comprehensive evaluations take 30-45 minutes, follow-ups 15-20 minutes. That’s 7-15 hours monthly for that $2,000 revenue — roughly $133-285/hour depending on efficiency.

Compare to psychiatry: Medication management visits typically reimburse $100-200 for 15-30 minutes ($200-400/hour effective rate). Weight management is less profitable per hour unless you can build efficiency through templated workflows.

Hidden costs:

State licensing fees if treating patients in multiple states ($500-1,500 per state)
DEA registration ($888 for 3 years)
PDMP registration and e-prescribing software ($200-500/year)
Liability insurance increase (may be minimal or could be significant depending on carrier)
Marketing to attract weight loss patients (significant if starting from scratch)
Time for care coordination and documentation

The patient acquisition reality: Unlike psychiatric care where patients often find you through insurance panels, weight loss is largely a cash-pay, consumer-driven market. Acquiring patients through DIY marketing (Google Ads, SEO, directories) typically costs $200-500+ per patient when you factor in all expenses — ad spend, optimization time, no-show rates, and months of effort before seeing results.

A different model: Instead of building weight loss infrastructure from scratch, some psychiatrists incorporate it selectively:

Help existing psychiatric patients manage medication-induced weight gain (already within your relationship and clinical scope)
Partner with primary care practices for co-management (they handle medical screening, you prescribe and monitor psychiatric medication interactions)
Join a platform that handles patient acquisition and infrastructure, allowing you to focus purely on clinical care

This last approach mirrors how platforms like Klarity Health work for psychiatric care: pre-qualified patients, built-in telehealth technology, no marketing spend, and you control your schedule. For weight management, a similar model would mean you pay a standard fee per appointment rather than gambling on marketing channels — guaranteed ROI versus uncertain outcomes.

When to Refer Instead of Prescribe

Refer to obesity medicine or endocrinology when:

BMI >40 (Class III obesity) — may need bariatric surgery evaluation
Complex metabolic conditions (diabetes requiring insulin adjustment, severe thyroid disease)
Patient failed multiple weight loss medication trials
Contraindications to medications you’re comfortable prescribing
Patient requests or needs more intensive lifestyle intervention programs
Any uncertainty about medical appropriateness

Refer to primary care when:

Patient lacks established primary care provider (they need one for comprehensive care)
Abnormal labs needing workup (elevated liver enzymes, kidney dysfunction, new diabetes)
Uncontrolled hypertension (>160/100) — needs optimization before starting weight loss meds
Patient needs in-person physical exam for diagnostic purposes

Refer to psychiatry/psychology when:

Active eating disorder (anorexia, bulimia) — weight loss medications contraindicated
Severe binge eating disorder needing specialized CBT
Body dysmorphic disorder
Unrealistic weight loss goals suggesting underlying mental health issues

Remember: Knowing your limits isn’t a weakness — it’s professional responsibility.

Looking Ahead: Prepare for 2027 Regulatory Changes

The current federal telehealth flexibilities for controlled substances expire December 31, 2026. While the DEA has proposed pathways to continue some remote prescribing (Special Telemedicine Registration for Schedule III-V, limited Schedule II prescribing for specialists), the final rules aren’t published.

What to expect:

Likely return of some in-person exam requirement for initial controlled substance prescriptions
Possible state-based restrictions (prescriber and patient must be in same state)
Potential quantity limits on telehealth prescriptions (e.g., 30-day supply maximum)
Additional training or certification requirements for telemedicine prescribers

How to prepare:

Build hybrid capability: Have a plan for in-person evaluations, either at your own office or through partner clinics in states where you practice.
Prioritize non-controlled medications: GLP-1s aren’t subject to DEA rules and are likely to remain freely prescribable via telehealth. Consider focusing there.
Stay informed: Monitor DEA rule-making through professional associations (American Psychiatric Association, American Telemedicine Association).
Document exceptional care now: If regulators review telehealth prescribing practices, comprehensive documentation of evaluations, follow-ups, and outcomes will demonstrate you met the standard of care.
Consider transitioning patients: If you have patients on phentermine via telehealth who’ll need in-person visits post-2026, start planning their transition — either to in-person care with you or to local providers.

FAQ

Can a psychiatrist prescribe Ozempic or Wegovy for weight loss?
Yes. Psychiatrists have full authority to prescribe GLP-1 medications for weight loss as long as they follow standard prescribing guidelines (appropriate patient evaluation, informed consent, monitoring). Since GLP-1s aren’t controlled substances, no special DEA rules apply. However, ensure you’re competent to manage these medications and coordinate with the patient’s primary care provider.

Do I need an in-person visit to prescribe weight loss medications via telehealth?
It depends on the state and medication. For non-controlled medications (GLP-1s), most states allow telehealth prescribing without an in-person visit as long as the evaluation meets the standard of care. For controlled substances (phentermine), current federal rules (through 2026) allow telehealth prescribing without in-person visits, but some states require in-person exams (New York definitely does; check your state). Always verify both federal and state requirements.

As a PMHNP, can I prescribe weight loss medications?
Legally complex. PMHNPs’ scope of practice is mental health, not general medical conditions like obesity. Most state nursing boards expect NPs to practice within their training. You would typically need physician collaboration (preferably with a primary care or obesity medicine physician, not a psychiatrist) to prescribe weight loss medications safely and within scope. If treating obesity as part of managing a psychiatric condition (e.g., binge eating disorder, medication-induced weight gain), you’re on stronger ground — but document the psychiatric indication clearly.

What’s the difference between prescribing Ozempic and phentermine from a regulatory perspective?
Ozempic/Wegovy (semaglutide) is not a controlled substance — no DEA registration needed, no PDMP checks required, generally fewer regulatory restrictions. Phentermine is a Schedule IV controlled substance — requires DEA registration, PDMP database checks in most states, subject to Ryan Haight Act rules (currently waived federally through 2026), and some states have additional restrictions on teleprescribing. From a clinical perspective, GLP-1s are generally safer with fewer abuse concerns, while phentermine has stimulant effects and contraindications in cardiovascular disease.

Do I need to check the PDMP every time I prescribe phentermine?
State-dependent. Some states (like Pennsylvania for benzodiazepines, New York for Schedule II-IV) require PDMP checks before every prescription. Others require checking before the first prescription and periodically thereafter (California requires at least every 4 months for ongoing controlled substance therapy). Even if not legally required at every refill, best practice is checking regularly — it takes 2 minutes and protects both you and the patient from duplicate prescriptions or contraindicated drug combinations.

Can I prescribe weight loss medications to patients in multiple states?
Only if you’re licensed in each state where patients are located. You must hold an active medical license in the state where the patient is physically located at the time of the telehealth visit. There’s no federal telehealth license. The Interstate Medical Licensure Compact (IMLC) can streamline getting multiple state licenses if you practice in member states, but you still need individual licenses. Prescribing to out-of-state patients without appropriate licensure is illegal and can result in license discipline.

How often do I need to see weight loss patients for follow-up?
Minimum requirements vary by state: Florida requires at least every 3 months, Virginia every 30 days, New Jersey mandates specific intervals based on medication type. From a clinical standard of care perspective, most obesity medicine guidelines recommend monthly follow-ups for the first 3 months (especially when titrating GLP-1 doses), then every 2-3 months once stable. More frequent monitoring is appropriate if side effects occur or dose adjustments are needed. Document your follow-up schedule and clinical justification.

What happens if DEA rules change in 2027 and I have patients on phentermine?
Start planning now. If new rules require in-person exams for controlled substance prescribing, you’ll need to either: (1) transition patients to local in-person providers, (2) establish physical office locations in states where you practice telehealth, (3) partner with clinics for in-person evaluations while you manage ongoing care, or (4) switch appropriate patients to non-controlled alternatives like GLP-1s. Communicate transparently with patients about potential changes. The DEA will likely provide a transition period.

Are there medical malpractice insurance considerations?
Yes. Notify your malpractice carrier if you’re prescri

Source:

Get expert care from top-rated providers

Find the right provider for your needs — select your state to find expert care near you.

All professional services are provided by independent private practices via the Klarity technology platform. Klarity Health, Inc. does not provide medical services.

Phone:

(866) 391-3314

— Monday to Friday, 7:00 AM to 4:00 PM PST

Fax:

(855) 975-3008

Email:

patientsupport@helloklarity.com

Mailing Address:

1825 South Grant St, Suite 200, San Mateo, CA 94402

Join our mailing list for exclusive healthcare updates and tips.

Stay connected to receive the latest about special offers and health tips. By subscribing, you agree to our Terms & Conditions and Privacy Policy.